Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations
Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2011.383
Full Text
Open PDFAbstract
Available in full text
Date
November 16, 2011
Authors
Publisher
Spandidos Publications